Dark

Check out our Dark Pool Levels

PRTK
Paratek Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Sep 20, 2023

2.23USD+1.826%(+0.04)4,764,401

Pre-market

0.00USD-100.000%(-2.19)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

04:05PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Dec 16, 2021

11:36AM EST China's National Medical Products Administration GlobeNewswire Inc

Dec 1, 2021

04:05PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Nov 9, 2021

11:28AM EST HC Wainwright & Co. Maintains Buy on Paratek Pharmaceuticals, Lowers Price Target to $27 Benzinga

11:17AM EST Recap: Paratek Pharmaceuticals Q3 Earnings Benzinga

11:08AM EST Paratek Pharmaceuticals Sees FY21 Sales $128M-$139M Vs. $135.17M Est. Benzinga

11:08AM EST Paratek Pharmaceuticals Q3 EPS $(0.37) Beats $(0.45) Estimate, Sales $24.45M Beat $23.82M Estimate Benzinga

Nov 8, 2021

04:05PM EST -- NUZYRA(omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter GlobeNewswire Inc

10:13AM EST Paratek Pharmaceuticals's Return On Capital Employed Insights Benzinga

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 1, 2021

04:05PM EDT Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m. EST to provide a corporate update and report its financial results for the third quarter ended Sept. 30, 2021. GlobeNewswire Inc

04:04PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Oct 18, 2021

04:08PM EDT Paratek Pharmaceuticals Announces Enrollment Of First Patient In Phase 2b Study Evaluating NUZYRA For Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused By Mycobacterium Abscessus Complex Benzinga

04:05PM EDT Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the companys Phase 2b study evaluating the safety and efficacy of NUZYRA (omadacycline) for the treatment for nontuberculous mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc), a rare disease for which there is no FDA-approved therapy. GlobeNewswire Inc

Oct 1, 2021

04:05PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Sep 30, 2021

08:02AM EDT Antimicrobials Working Group Highlights Member Company Participation at IDWeek PR Newswire

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 27, 2021

04:06PM EDT Paratek Pharma Reports $19M In Added Funding Under BARDA Contract To Advance Development Of NUZYRA For Post-Exposure Prophylaxis, Treatment Of Pulmonary Anthrax; BARD Contract Now Valued At $304M Benzinga

04:05PM EDT -- Additional ~$19M Funding for Expanded Anthrax PEP Development Program GlobeNewswire Inc

Sep 23, 2021

04:10PM EDT Paratek To Present New Data For NUZYRA At IDWeek 2021 Wednesday, Sept. 29 Benzinga

04:05PM EDT Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting. GlobeNewswire Inc

Sep 17, 2021

10:38AM EDT How Good Are Paratek Pharmaceuticals's Earnings? | Return On Capital Employed Benzinga

Sep 9, 2021

08:30AM EDT Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual GlobeNewswire Inc

Sep 1, 2021

04:05PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

06:36AM EDT Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection Benzinga

Aug 18, 2021

04:12PM EDT Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for GlobeNewswire Inc

08:50AM EDT Paratek Pharmaceuticals Granted Orphan Drug Designation For Treatment Of Infections Caused By Nontuberculous Mycobacteria Benzinga

Aug 9, 2021

05:08PM EDT Paratek Pharmaceuticals: Q2 Earnings Insights Benzinga

04:59PM EDT Paratek Pharmaceuticals Q2 EPS $0.20 Misses $0.31 Estimate, Sales $57.49M Miss $60.99M Estimate Benzinga

04:05PM EDT -- NUZYRA(omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter GlobeNewswire Inc

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

08:02AM EDT Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire

Aug 4, 2021

04:34PM EDT Paratek Pharma Reports NUZYRA Added To CDC Plague Guidelines For Treatment, Pre-Exposure, Postexposure Prophylaxis Of Plague Benzinga

Aug 2, 2021

04:35PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

04:30PM EDT Paratek Pharmaceuticals to Report Second Quarter 2021 Financial GlobeNewswire Inc

Jun 29, 2021

08:01AM EDT Paratek Pharma Reports First Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Procurement Of NUZYRA, Valued At $38M Benzinga

08:00AM EDT Paratek Pharmaceuticals Announces First BARDA Project BioShield GlobeNewswire Inc

Jun 21, 2021

07:53AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:24AM EDT HC Wainwright & Co. Maintains Buy on Paratek Pharmaceuticals, Raises Price Target to $28 Benzinga

Jun 16, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Federal Reserve Maintains Interest Rates Benzinga

12:03PM EDT Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge Benzinga

09:33AM EDT Paratek Launches Mid-Stage NTM Program With Nuzyra, Second Procurement Under BARDA Pact Expected In 2H 2022 Benzinga

08:06AM EDT Biopharmaceutical company Paratek Pharmaceuticals, Inc. (PRTK) announced Wednesday the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial (NTM) pulmonary disease caused by mycobacterium abscessus complex (MABc). RTTNews

07:36AM EDT Paratek Reports Initiation Of Clinical Trial Sites For Phase 2b Study On Potential Utility Of NUZYRA RTTNews

07:32AM EDT Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium Abscessus Complex with NUZYRA Benzinga

07:30AM EDT -- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment GlobeNewswire Inc

Jun 14, 2021

08:27AM EDT Paratek Pharma Appoints Minnie Baylor-Henry To Board RTTNews

08:00AM EDT Paratek Appoints Minnie Baylor-Henry to Companys GlobeNewswire Inc

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

08:00AM EDT Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that it will host an investor webinar on Wednesday, June 16, 2021, at 10:00 a.m. Eastern Time. GlobeNewswire Inc

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 8, 2021

11:19AM EDT Crestone Joins Antimicrobials Working Group PR Newswire

Jun 4, 2021

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

Jun 3, 2021

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

Jun 2, 2021

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

Jun 1, 2021

04:05PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

09:38AM EDT Paratek's Stock Gains After Nuzyra's Oral Regime Wins FDA Approval For Pneumonia Benzinga

07:46AM EDT Paratek Pharmaceuticals Announces FDA Approval Of NUZYRA Oral Only Dosing Regimen For Treatment Of Community-Acquired Bacterial Pneumonia Benzinga

07:45AM EDT - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion GlobeNewswire Inc

May 26, 2021

04:18PM EDT Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare GlobeNewswire Inc

May 17, 2021

01:33PM EDT ROCE Insights For Paratek Pharmaceuticals Benzinga

08:13AM EDT Paratek Pharmaceuticals May Offer, Sell Shares Of Common Stock Having Offering Price Of Up To $50M From Time To Time Benzinga

07:47AM EDT Paratek Pharmaceuticals: Q1 Earnings Insights Benzinga

07:38AM EDT Paratek Pharmaceuticals Q1 EPS $(0.39) Misses $(0.38) Estimate, Sales $16.43M Miss $28.72M Estimate Benzinga

07:30AM EDT -- NUZYRA(omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 10, 2021

04:05PM EDT Paratek Pharmaceuticals to Report First Quarter 2021 Financial GlobeNewswire Inc

May 3, 2021

04:01PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Apr 23, 2021

12:03PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 23, 2021 Benzinga

07:25AM EDT WBB Securities Upgrades Paratek Pharmaceuticals to Buy, Announces $10 Price Target Benzinga

Apr 1, 2021

04:01PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Mar 2, 2021

11:17AM EST Jefferies Initiates Coverage On Paratek Pharmaceuticals with Buy Rating, Announces Price Target of $15 Benzinga

Mar 1, 2021

04:01PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Feb 24, 2021

04:08PM EST Paratek Pharmaceuticals Sees FY21 Sales $166M-$177M Vs. $182.84M Est. Benzinga

04:07PM EST Paratek Pharmaceuticals Q4 EPS $(0.54) Misses $(0.04) Estimate, Sales $16.00M Up From $8.97M YoY Benzinga

04:01PM EST -- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 18, 2021

04:01PM EST Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink GlobeNewswire Inc

Feb 17, 2021

04:01PM EST Paratek Pharmaceuticals to Report Fourth Quarter and Full Year GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

08:28AM EST Paratek Announces Expansion Of NUZYRA Launch Into Community Setting Benzinga

08:00AM EST Paratek Announces Expansion of NUZYRA Launch into the GlobeNewswire Inc

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 1, 2021

04:05PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Jan 6, 2021

08:00AM EST Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright GlobeNewswire Inc

Jan 4, 2021

05:00PM EST Paratek Pharma Reports Received $600M Non-Recourse Loan From R-Bridge Healthcare Investment Advisory Benzinga

05:00PM EST Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan GlobeNewswire Inc

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 1, 2020

04:05PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Nov 12, 2020

04:01PM EST Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual GlobeNewswire Inc

Nov 9, 2020

06:42AM EST HC Wainwright & Co. Maintains Buy on Paratek Pharmaceuticals, Raises Price Target to $22 Benzinga

Nov 5, 2020

04:07PM EST Paratek Pharmaceuticals Q3 EPS $(0.46) Beats $(0.61) Estimate, Sales $13.66M Beat $11.90M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

04:05PM EST Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 27, 2020

08:00AM EDT Paratek Pharmaceuticals to Report Third Quarter 2020 Financial GlobeNewswire Inc

Oct 21, 2020

08:00AM EDT Paratek Pharmaceuticals Presenting New Data on NUZYRA GlobeNewswire Inc

Sep 9, 2020

04:01PM EDT Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual GlobeNewswire Inc

Sep 1, 2020

04:05PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Aug 11, 2020

11:55AM EDT HC Wainwright & Co. Maintains Buy on Paratek Pharmaceuticals, Raises Price Target to $19 Benzinga

05:00AM EDT SVB Leerink Maintains Outperform on Paratek Pharmaceuticals, Lowers Price Target to $14 Benzinga

Aug 10, 2020

08:12AM EDT Recap: Paratek Pharmaceuticals Q2 Earnings Benzinga

07:42AM EDT Paratek Pharmaceuticals Raises FY20 Sales guidance From $75M-$80M vs $78M-$83M vs $81.16M Est. Benzinga

07:42AM EDT Paratek Pharmaceuticals Q2 EPS $(0.53) May Not Compare To $(0.06) Estimate, Sales $9.30M May Not Compare To $38.03M Estimate Benzinga

07:42AM EDT -- Paratek Raises Full Year2020 Revenue Guidance; TotalRevenue guidance expectedtobeBetween$78and$83 MillionDriven by Strong NUZYRANet Revenue GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 5, 2020

04:01PM EDT Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at two upcoming healthcare conferences. GlobeNewswire Inc

Aug 3, 2020

04:05PM EDT Paratek Announces Inducement Grants under NASDAQ Listing Rule GlobeNewswire Inc

Jul 28, 2020

04:01PM EDT Paratek Pharmaceuticals to Report Second Quarter 2020 Financial GlobeNewswire Inc

Share